

Contents

Preface iii

Contributors xiii

PART I: GENERAL

1. Retinal Drug Delivery 1

Paul Ashton

Basic Principles of Drug Delivery 1

Drug Delivery to the Posterior Segment of the Eye 8

Drug Elimination Mechanisms 12

Posterior Delivery in Disease States 14

Photodynamic Therapy 18

Future Opportunities and Challenges 19

References 19

2. Blood–Retinal Barrier 27

David A. Antonetti, Thomas W. Gardner, and Alistair J. Barber

Introduction 27

Function of the Blood–Retinal Barrier 27

Formation of the Blood–Neural Barrier 28

Ocular Disease and Loss of the Blood–Retinal Barrier 29

Molecular Architecture of the Blood–Retinal Barrier 30

Claudins 30

Occludin 31

Restoring Barrier Properties 33

References 34

3. Neuroprotection 41

Dennis W. Rickman and Melissa J. Mahoney

Introduction 41

Excitotoxicity as a Stimulus for Neuronal Cell Death 41

Intracellular Effectors of Cell Death 43

Oxidative Stress and the Generation of Free Radicals 45

Neurotrophins and Neurotrophin Deprivation as a Stimulus
for Retinal Cell Death 46

Neurotrophins Support the Development and Maintenance of Retinal Ganglion Cells	46
Neurotrophins Support the Development of Inner Retinal Circuitry	47
Models of Photoreceptor Degeneration and Strategies for Their Treatment	47
Neurotrophin Delivery to CNS Tissue	48
Summary	50
References	51
4. Regulatory Issues in Drug Delivery to the Eye	59
<i>Lewis J. Gryziewicz and Scott M. Whitcup</i>	
Introduction	59
Drug Development in the United States	60
References	69
PART II: SPECIFIC DELIVERY SYSTEMS	
5. Antiangiogenic Agents: Intravitreal Injection	71
<i>Sophie J. Bakri and Peter K. Kaiser</i>	
Introduction	71
Intravitreal Injection	72
Technique for Intravitreal Injection	72
VEGF	73
References	81
6. Intravitreal Antimicrobials	85
<i>Travis A. Meredith</i>	
Introduction	85
Basic Pharmacokinetics	85
Intravitreal Injections	87
Therapeutic Concentration Range	89
Toxicity	89
Characteristics of Selected Antimicrobials	91
References	93
7. Pharmacologic Retinal Reattachment with INS37217 (Denufosol Tetrasodium), a Nucleotide P2Y₂ Receptor Agonist	97
<i>Ward M. Peterson</i>	
Description of Drug Delivery System	97
Spectrum of Diseases	97
Mechanism of Action	99
Animal Models of Disease Used	100
Results of Animal Model Studies	101
Drug Delivery and Distribution	105
Clinical Study	107
Future Horizons	108
References	109

8. Cell-Based Delivery Systems: Development of Encapsulated Cell Technology for Ophthalmic Applications 111
Weng Tao, Rong Wen, Alan Laties, and Gustavo D. Aguirre
 Description of Encapsulated Cell Technology 111
 Spectrum of Diseases for Which This Delivery System
 Might Be Appropriate 116
 Animal Models Used to Investigate the Applicability
 of this Delivery System for the Diseases Mentioned 118
 Pharmacokinetic and Pharmacodynamic Studies
 Using the Delivery System 120
 Results of Animal Model Studies 120
 Techniques for Implanting or Placing the Implant in
 Humans 124
 Future Horizons 126
 References 126

9. Photodynamic Therapy 129
Ivana K. Kim and Joan W. Miller
 Introduction 129
 Preclinical Studies of Verteporfin for Experimental CNV 130
 Other Photosensitizers 136
 Future Directions 137
 References 139

10. Thermal-Sensitive Liposomes 143
Sanjay Asrani, Morton F. Goldberg, and Ran Zeimer
 Introduction 143
 Methodology of Laser-Targeted Drug Delivery 144
 Potential Therapeutic Applications of LTD 147
 Diagnostic Applications 149
 Safety of Light-Targeted Drug Delivery 152
 Limitations 153
 Conclusion 153
 Disclosure of Financial Interest 154
 References 154

11. Gene Therapy for Retinal Disease 157
Albert M. Maguire and Jean Bennett
 Description of Drug Delivery System 157
 Spectrum of Diseases for Which This Delivery System
 Might Be Appropriate 160
 Animal Models Used to Investigate the Applicability of This
 Delivery System for the Diseases Mentioned Above 162
 Pharmacokinetic Studies Using the Delivery System 163
 Results of Animal Model Studies 163

Techniques for Implanting or Placing the Implant in Humans (If Done)	167
Future Horizons	168
References	169
12. Biodegradable Systems	175
<i>Hideya Kimura and Yuichiro Ogura</i>	
Fundamentals of Biodegradable Polymeric Devices	175
Spectrum of Diseases for Which Biodegradable Systems May Be Useful	179
Animal Models Used to Test Biodegradable Drug Delivery Systems	180
Results of Efficacy Studies	181
Pharmacokinetic and Pharmacodynamic Studies	183
Summary and Future Horizons	189
References	189
13. Transscleral Drug Delivery to the Retina and Choroid	193
<i>Jayakrishna Ambati</i>	
Introduction	193
Scleral Anatomy	193
In Vitro Studies of Scleral Permeability	194
In Vivo Studies of Scleral Permeability	196
Future Directions	198
References	199
14. Nondegradable Intraocular Sustained-Release Drug Delivery Devices	203
<i>Mark T. Cahill and Glenn J. Jaffe</i>	
Implanted Nondegradable Sustained-Release Devices	203
Implanted Microdialysis Probes as Sustained-Release Drug Delivery Systems	216
Microelectromechanical Systems Drug Delivery Devices	219
References	222
PART III: LOCAL DRUG DELIVERY APPROACH TO SPECIFIC CLINICAL DISEASES	
15. Photodynamic Therapy in Human Clinical Studies: Age-Related Macular Degeneration	227
<i>Ivana K. Kim and Joan W. Miller</i>	
Introduction	227
Phase I/II Design and Methodology	227
Phase I/II Results	231
Phase III Design/Methodology	234

Conclusions	244
References	245
16. Age-Related Macular Degeneration Drug Delivery	249
<i>Kourous A. Rezaei, Sophie J. Bakri, and Peter K. Kaiser</i>	
Treatment Modalities for Neovascular AMD	249
Clinical Trials of Drug Delivery Devices for the Treatment of Neovascular AMD	250
References	259
17. Intraocular Sustained-Release Drug Delivery in Uveitis	265
<i>Mark T. Cahill and Glenn J. Jaffe</i>	
Introduction	265
Corticosteroid Devices	266
Cyclosporine Devices	275
Conclusions	276
References	277
18. Drug Delivery for Proliferative Vitreoretinopathy: Prevention and Treatment	279
<i>Stephen J. Phillips and Glenn J. Jaffe</i>	
Retinal Detachment/Proliferative Vitreoretinopathy	279
Systemic	282
Local Delivery	283
Direct Injection—Subconjunctival or Intravitreal	283
Sustained Delivery and Co-Drugs	286
References	287
19. Pharmacologic Treatment in Diabetic Macular Edema	291
<i>Zeshan A. Rana and P. Andrew Pearson</i>	
Introduction	291
Treatment	292
Corticosteroids	292
Intravitreal Triamcinolone Acetonide (Kenalog) Injection	293
Intravitreal Fluocinolone Acetonide Implant (Retisert)	294
Dexamethasone Implant (Posurdex [®])	295
Protein Kinase C Inhibition	296
VEGF Inhibition	297
New Agents on the Horizon	297
References	298
20. Retinal Vein Occlusion	301
<i>Michael M. Altaweel and Michael S. Ip</i>	
Local Drug Delivery Approach: Retinal Vein Occlusion	301

Other Treatments	309
Summary	319
References	320
21. Cytomegalovirus Retinitis	325
<i>Caroline R. Baumal</i>	
Introduction	325
Virology and Epidemiology of CMV Infection	327
CMV Retinitis in the Era of HAART	327
Clinical Features of CMV Retinitis	328
Diagnosis of CMV Retinitis	330
Treatment of CMV Retinitis	330
Systemic Anti-CMV Therapy	331
Local Modes of Intraocular Drug Delivery	333
Intravitreal Drug Injection	334
The Ganciclovir Intraocular Implant	335
Indications for the Ganciclovir Implant	339
Replacement of the Ganciclovir Implant	340
Complications of the Ganciclovir Implant	341
Summary	342
References	343
22. Endophthalmitis	349
<i>Travis A. Meredith</i>	
Overview	349
Presentation	349
Predisposing Factors	349
Bacterial Spectrum	350
Antimicrobial Therapy	350
Injection of Intraocular Corticosteroids	352
Prognosis	353
Summary	353
References	353
<i>Index</i>	<i>357</i>